Loading...
Sickle cell disease can have devastating clinical consequences, from anemia, vaso-occlusion, end organ insult, and thrombosis. The therapeutic landscape is finally extending beyond hydroxyurea, which has important clinical benefits. Hematologists now have access to L-glutamine, crizanlizumab, and voxelotor, which help ameliorate pain and improve anemia. However, these agents do not lead to cure. Hematopoietic stem cell transplantation (HSCT) can be curative and is a consideration for selected patients. A panel convened by ASH developed recommendations for HSCT in the clinical care of patients with sickle cell anemia; recommendations were considered stro…